Making the Case to Use JAK Inhibitors for Rheumatoid Arthritis"Who, What, When, and How

Target Audience
This activity has been designed to address the educational needs of rheumatology clinicians. It may also benefit other clinicians involved in the management of patients with rheumatoid arthritis (RA).

Program Overview
Join Dr Rigby and Dr Troum as they discuss the use of Janus kinase (JAK) inhibitors for the treatment of RA. In this program they will discuss the latest post-hoc analysis of the ORAL Surveillance trial, which shows which patients can safely and effectively use JAK inhibitors to reduce the symptoms of RA. They will also present data showing how JAK inhibitors positively influence patient-reported outcomes, such as depression and pain. In this presentation, JAK inhibitor efficacy and safety is shown in comparison with tumor necrosis factor inhibitors and methotrexate to provide a current landscape of treatment options for RA.

Learning Objectives
Upon completion of this activity, participants should be able to:

Describe the role of the JAK1-specific pathways in the pathophysiology of RA and the effects of selected JAK inhibition
Interpret available safety and efficacy data regarding JAK inhibitors to treat RA
Formulate appropriate treatment plans for patients with RA